Speciality
Spotlight

 




 


Endocrinology


   

  




Hyperprolactinemia

     

  • Two year treatment with oral
    contraceptives in hyperprolactinemic patients
    .

    G
    Testa, et al (Universita di Pavia, Varese, Italy;
    Universita di Milano, Italyu; Istituto Ricerche
    Farmacologiche ” Mario Negir,” Milano,
    Italy)   Contraception
    58: 69-73, 1998
    .

      

    The
    objective of the study has been that increased use
    of oral contraceptives (Ocs)
    may play a role in the development of pituitary
    prolactin secreting adenoma.
    The symptoms, serum PRL levels, and
    radiologic aspects of a group of young patients with
    hyperprolactinemia after 2 years of OC intake were
    prospectively assessed.

       

    Conclusion-
    Endogenous or exogenous estrogen treatment does not
    promote growth of pituitary adenomas after 2 years.

        

    Editorial
    comments
    :  Clinical problems associated with
    hyperprolactinemia include anovulatory irregular
    bleeding and hypoestrogenism. Treatment with bromocriptine usually induces
    ovulatory cycles, causes regular bleeding, and
    raises estrogen levels. However, bromocriptine therapy is expensive
    and has adverse effects. Thus if a woman with hyperprolactinomia
    without a pituitary micoradenoma does not wish to
    conceive, she can be treated with low-dose Ocs. 
    Regular bleeding episodes occur, and the
    estrogen in the OC will prevent bone loss. Adverse effects are less with Ocs
    than bromocriptine and Ocs. Like pregnancy, they do not stimulate the
    growth of prolactin secreting microadenomas.

      

  • There
    are 2 articles on the impaired glucose tolerance and
    diabetes in women with polycystic ovary syndrome.

     

    1)  
    Prevalence
    of Impaired Glucose Tolerance and Diabetes in Women
    with Polycystic Ovary Syndrome
    .

       

           
    DA Ehrmann, et al (Univ of Chicago). 
    Diabetes Care  22: 141-146,
    1999.

     

    2)   
    Prevalence and Predictors of Risk for Type 2
    Diabetes Mellitus and Impaired Glucose Tolerance
    in Polycystic Ovary Syndrome:
    A Prospective, Controlled Study in 254
    Affected Women.

      

 



 

 

Speciality Spotlight

 

 
Endocrinology
   

  

Hyperprolactinemia
     

  • Two year treatment with oral contraceptives in hyperprolactinemic patients.
    G Testa, et al (Universita di Pavia, Varese, Italy; Universita di Milano, Italyu; Istituto Ricerche Farmacologiche ” Mario Negir,” Milano, Italy)   Contraception 58: 69-73, 1998.
      
    The objective of the study has been that increased use of oral contraceptives (Ocs) may play a role in the development of pituitary prolactin secreting adenoma. The symptoms, serum PRL levels, and radiologic aspects of a group of young patients with hyperprolactinemia after 2 years of OC intake were prospectively assessed.
       
    Conclusion- Endogenous or exogenous estrogen treatment does not promote growth of pituitary adenomas after 2 years.
        
    Editorial comments:  Clinical problems associated with hyperprolactinemia include anovulatory irregular bleeding and hypoestrogenism. Treatment with bromocriptine usually induces ovulatory cycles, causes regular bleeding, and raises estrogen levels. However, bromocriptine therapy is expensive and has adverse effects. Thus if a woman with hyperprolactinomia without a pituitary micoradenoma does not wish to conceive, she can be treated with low-dose Ocs.  Regular bleeding episodes occur, and the estrogen in the OC will prevent bone loss. Adverse effects are less with Ocs than bromocriptine and Ocs. Like pregnancy, they do not stimulate the growth of prolactin secreting microadenomas.
      

  • There are 2 articles on the impaired glucose tolerance and diabetes in women with polycystic ovary syndrome.
     
    1)   Prevalence of Impaired Glucose Tolerance and Diabetes in Women with Polycystic Ovary Syndrome.
       
            DA Ehrmann, et al (Univ of Chicago).  Diabetes Care  22: 141-146, 1999.
     
    2)    Prevalence and Predictors of Risk for Type 2 Diabetes Mellitus and Impaired Glucose Tolerance in Polycystic Ovary Syndrome: A Prospective, Controlled Study in 254 Affected Women.
      

 

 

By |2022-07-20T16:41:29+00:00July 20, 2022|Uncategorized|Comments Off on Hyperprolactinemia

About the Author: